Jesus Berganza

Jesus Berganza

Auto-generated profile, based on publicly available information

Jesus Berganza

GAIKER Technology Centre, Basque Research and Technology Alliance (BRTA), Parque Tecnológico de Bizkaia, Edificio 202, 48170 Zamudio, Spain

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
MMM. Mujika
M. Mujika
SAS. Arana
S. Arana
ECE. Castaño
E. Castaño
MTM. Tijero
M. Tijero
RVR. Vilares
R. Vilares
JBJ. Berganza
J. Berganza

13 January 2021 in Nanoscale Advances
Verified
Journal Article
Open access
PDF file
MRMaría V. Romeo
María V. Romeo
ELElena López-Martínez
Elena López-Martínez
JBJesús Berganza-Granda
Jesús Berganza-Granda
FCFelipe Goñi De Cerio
Felipe Goñi De Cerio
ACAitziber Cortajarena
Aitziber Cortajarena
Metal nanoclusters and their unique properties are increasing in importance. In this review we acknowledge their application as sensors for biomarkers and the current state in preclinical and clinical uses.

1 April 2007 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
JBJ. Berganza
J. Berganza
Garbiñe OlabarríaGarbiñe Olabarría
Garbiñe Olabarría
RGRaquel Garcia
Raquel Garcia
DVD. Verdoy
D. Verdoy
ARA. Rebollo
A. Rebollo
SAS. Arana
S. Arana

1 September 2020 in Talanta
Verified
Journal Article
Closed access
Garbiñe OlabarríaGarbiñe Olabarría
Garbiñe Olabarría
UEUnai Eletxigerra
Unai Eletxigerra
IRIsabel Rodriguez
Isabel Rodriguez
AINHOA BILBAOAINHOA BILBAO
AINHOA BILBAO
JBJesus Berganza
Jesus Berganza
SMSantos Merino
Santos Merino

1 November 2012 in Talanta
Verified
Journal Article
Closed access
TAT. Arnandis-Chover
T. Arnandis-Chover
Sergi MoraisSergi Morais
Sergi Morais
Luis Antonio Tortajada-GenaroLuis Antonio Tortajada-Genaro
Luis Antonio Tortajada-Genaro
RPR. Puchades
R. Puchades
Ángel MaquieiraÁngel Maquieira
Ángel Maquieira
Garbiñe OlabarríaGarbiñe Olabarría
Garbiñe Olabarría

1 September 2018 in Cancers
Verified
Journal Article
Open access
PDF file
Joaquin CubiellaJoaquin Cubiella
Joaquin Cubiella
MCMarc Clos-Garcia
Marc Clos-Garcia
CACristina Alonso
Cristina Alonso
IMIbon Martinez-Arranz
Ibon Martinez-Arranz
MPMiriam Perez-Cormenzana
Miriam Perez-Cormenzana
JFJuan M Falcon-Perez
Juan M Falcon-Perez
Low invasive tests with high sensitivity for colorectal cancer and advanced precancerous lesions will increase adherence rates, and improve clinical outcomes. We have performed an ultra-performance liquid chromatography/time-of-flight mass spectrometry (UPLC-(TOF) MS)-based metabolomics study to identify faecal biomarkers for the detection of patients with advanced neoplasia. A cohort of 80 patients with advanced neoplasia (40 advanced adenomas and 40 colorectal cancers) and 49 healthy subjects were analysed in the study. We evaluated the faecal levels of 105 metabolites including glycerolipids, glycerophospholipids, sterol lipids and sphingolipids. We found 18 metabolites that were significantly altered in patients with advanced neoplasia compared to controls. The combinations of seven metabolites including ChoE(18:1), ChoE(18:2), ChoE(20:4), PE(16:0/18:1), SM(d18:1/23:0), SM(42:3) and TG(54:1), discriminated advanced neoplasia patients from healthy controls. These seven metabolites were employed to construct a predictive model that provides an area under the curve (AUC) median value of 0.821. The inclusion of faecal haemoglobin concentration in the metabolomics signature improved the predictive model to an AUC of 0.885. In silico gene expression analysis of tumour tissue supports our results and puts the differentially expressed metabolites into biological context, showing that glycerolipids and sphingolipids metabolism and GPI-anchor biosynthesis pathways may play a role in tumour progression.